Upcoming Event: Asia Pharma R&D Leaders 2011
10/28/2010
Event: Asia Pharma R&D Leaders 2011
Dates: March 24 - 25, 2011
Venue: InterContinental Pudong, Shanghai, China
Contact: Daniel Chen
Tel: +86 21 3251 6046
Why big pharma invest heavily in China? What's hot in 2011 and beyond?
Find out the answer at Asia Pharma R&D Leaders 2011-the most premier pharma R&D event in China with Asia perspectives. The 2011 version of Asia Pharma R&D Event will bring in fresh perspectives and scientific advancement on popular therapeutic areas in cancers, CNS, and metabolic diseases which big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, licensing opportunities, risk management approaches, outsourcing strategies, IP management, and latest pharma research advancement on sequencing, biomarkers, preclinical imaging, data management etc necessary to optimize your pharma R&D cost efficiency and gain competitiveness in Asia.
At a time of "Pharma R&D: Thinking big, acting small", Asia Pharma R&D Leaders (APRDL) is staged back again to present another great event for pharma R&D industry leaders all over the world with special interests in pharma R&D opportunities in Asian emerging markets and with views to optimize their R&D capabilities in the region. Asia Pharma R&D Leaders 2011 (APRDL 2011) will provide you with the best practice you need to know for wining emerging market in Asia. This event also provides excellent networking opportunities by way of a speed networking sessions where attendees will exchange details and make new contacts, as well as our contact system, which will allow participants to arrange meetings and email conference with attendees, speakers and the press.
An updated list of 2011 summit's highlighted topics:
- Latest advancement in Biomarker, Antibody, and Peptide discoveries;
- New business models in 2011 and beyond for pharma R&D geared toward cost efficiency and ROI improvement;
- Asia market trends for heavily invested therapeutics areas: Oncology, CNS and Metabolic Diseases; and
- Effective partnership with top China CRO, biotech and academia
Plus, the event sets up an effective platform for attendees to meet 1 on 1 with a variety of Asia's local CROs and leading clinical practitioners to discuss the specifics of outsourcing requirements.
An international audience consisting of senior-level pharma and biotech executives from the R&D, clinical development, business development, global market access, licensing, and regulatory affairs functions will be in attendance.